Study of DA-9801 to Treat Diabetic Neuropathy

Diabetic Neuropathy Clinical Trial

Official title:

A Phase II Randomized, Double-Blind, Parallel Group, Dose-Ranging, Placebo-Controlled Study to Assess the Safety And Effectiveness Of DA-9801 in the Treatment of Subjects With Diabetic Neuropathy

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01822925
• Other study ID #: DA9801-DN-001
• Status: Completed
• Phase: Phase 2
• Start date: November 2013
• Est. completion date: January 2015

Study information

• Verified date: March 2020
• Source: NeuroBo Pharmaceuticals Inc.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

To evaluate the effectiveness of DA-9801 at 300mg, 600mg, 900mg and placebo, in reducing pain in subjects with diabetic neuropathic pain compared to their baseline values.

Description:

This is a double-blind, randomized, parallel group, dose ranging, placebo-controlled study where eligible subjects (age 18 to 75 years) will have an average pain score ≥ 4 on an 11-point Likert numerical rating scale (NRS) for at least four days each week prior to randomization as assessed by daily pain diaries. Eligible subjects will be randomized to a 1:1:1:1 ratio to receive 300mg, 600mg, 900mg of DA-9801, or placebo three times a day for 12 weeks. During and at the end of the 12-week treatment period subjects will be evaluated for safety and efficacy parameters. A follow-up visit for safety will occur two weeks after the last treatment visit (TV).

The Screening Phase (2 weeks) is designed to determine whether subjects are eligible to proceed to the Treatment Phase of the study and consists of a series of screening assessments designed to determine eligibility. Eligible subjects will undergo a two-week washout period for medications and therapies administered for pain management.

At or up to 21 days before the Screening Visit, written informed consent from (ICF) the subject will be obtained by the Investigator or a suitably qualified designee before the performance of any protocol specific procedure. At the Screening Visit, the subject will be issued a daily diary in order to record daily pain level during the screening phase.

The Treatment Phase (TV0 to TV12) begins with a series of assessments designed to confirm the subjects' continued eligibility. The site will collect the daily diary and the subject's pain score will be determined. Only subjects whose average pain score is ≥ 4 for at least four days each week will be randomized to any of the four treatment groups.

DA-9801 administration schedule is three times per day, starting from TV0 to TV12.

During this study phase subjects will be evaluated on a weekly basis. Efficacy evaluations each week will include the subject's global impression of improvement and CGI of pain. Safety evaluations during the Treatment Phase will consist of adverse event assessments at each visit.

The Follow-up Visit (two weeks after last TV) The Follow-up Visit is designed to assess safety and will occur 14 days after the last TV. If the subject is withdrawn from the study prior to TV12, the subject should be exited from the study AFTER completing the specified assessments for that visit.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 128
• Est. completion date: January 2015
• Est. primary completion date: January 2015
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria:

• Must be 18 to 75 years of age

• Diagnosed with Type I or Type II diabetes

• HbA1c = 12% at the time of screening

• Has diabetic neuropathic pain (numbness, soreness, shooting or poking pain) in the lower extremities for more than 3 months prior to screening and with no adequate relief from other treatments

• Has an average pain score of = 4 for 24 hours at least 4 days out of the week prior to randomization as assessed by the 11-point Likert NRS.

• If female of childbearing potential, subject must have a negative serum pregnancy test at screening

• Understands and is willing to participate in the clinical study and can comply with study procedures and visits.

• Normal cognitive and communicative ability as judged by clinical assessment and ability to complete self-reported questionnaires

• Subject is willing and able to give informed consent

Exclusion Criteria:

• Evidence of another type of neuropathic pain caused by a condition other than diabetes

• Pain from another source as severe or greater than the pain under study

• BMI (Body Mass Index) > 37 kg/m2

• Clinical signs of infection related to sores of any type on the legs

• Subjects on any investigational drug(s) or therapeutic device(s) within 30 days preceding screening; or subject or physician anticipates use of any of these therapies by the subject during the course of the study

• Previous participation in the Treatment Phase of this Protocol

• History of drug or alcohol abuse, within the past 6 months

• Malignant disease not in remission for 5 years or more that has been medically or surgically treated without evidence of metastases

• Presence of one or more medical conditions, as determined by medical history, which seriously compromises the subject's ability to complete the study, including history of poor adherence with medical treatment, renal, hepatic, hematologic, active auto-immune or immune diseases that, in the opinion of the Investigator, would make the subject an inappropriate candidate for this study: c) One or more abnormal blood biochemistry analyte result that is = 3 times that of the upper limit of the normal range; d) For laboratory results that are significantly lower than the normal range, specific criteria will be used to judge subject eligibility for randomization for Total protein, Albumin, and Hemoglobin or Platelets.

• Known history of having Acquired Immunodeficiency Syndrome (AIDS) or with a history known to be infected with Human Immunodeficiency Virus (HIV)

• New York Heart Association (NYHA) Class III and IV congestive heart failure (CHF), as defined by the following criteria: a)Class III: Symptoms with moderate exertion b)Class IV: Symptoms at rest

• Pregnant or breast feeding

• Women of child-bearing potential not using an effective birth control method. Women of child-bearing potential are defined as women physiologically capable of becoming pregnant, UNLESS they meet the following criteria:

d) Post-menopausal: 12 months of natural (spontaneous) amenorrhea or 6 months of spontaneous amenorrhea with serum Follicle Stimulating Hormone (FSH) levels > 40mIU/m, OR; e) 6 weeks post surgical bilateral oophorectomy with or without hysterectomy, OR; f) Are using one or more of the following acceptable methods of contraception: surgical sterilization, hormonal contraception, and double-barrier methods. Reliable contraception should be maintained throughout the study and for 7 days after study discontinuation.

• Subjects with a diagnosis of psychiatric disorders such as major depressive disorder, bipolar disorder, obsessive compulsive disorder, generalized anxiety, dysthymia or suicidality/suicide ideation

• Administration of local anesthetic shot or systemic steroids within two months of screening

• Subjects not willing to undergo a two-week washout period for pharmacologic and non-pharmacologic pain management techniques

Related Conditions & MeSH terms

• Diabetic Neuropathies
• Diabetic Neuropathy
• Peripheral Nervous System Diseases

Intervention

Drug:
• DA-9801 300mg
300 mg of DA-9801 in tablet form, 100 mg to be taken 3 times daily for 12 weeks.
• DA-9801 600mg
600 mg of DA-9801 in tablet form, 200 mg to be taken 3 times daily for 12 weeks.
• DA-9801 900mg
900 mg of DA-9801 in tablet form, to be taken 300 mg to be taken 3 times daily for 12 weeks.
• Placebo
Placebo, in tablet form, to be taken 3 times daily for 12 weeks. The placebo is the same formulation as DA-9801 except that it does not contain the active pharmaceutical ingredient.

Locations

Country	Name	City	State
United States	Albany Medical Center	Albany	New York
United States	Johns Hopkins University	Baltimore	Maryland
United States	PAB Clinical Research	Brandon	Florida
United States	KRK Research	Dallas	Texas
United States	North Texas Endocrine Center	Dallas	Texas
United States	Houston Foot & Ankle Care	Houston	Texas
United States	Center for United Research, Inc.	Lakewood	California
United States	Clinical Research Consulting, LLC	Milford	Connecticut
United States	Coastal Carolina Research Center	Mount Pleasant	South Carolina
United States	Novex Clinical Research, Inc.	New Bedford	Massachusetts
United States	Rainier Clinical Research Center, Inc.	Renton	Washington
United States	Wasatch Clinical Research	Salt Lake City	Utah
United States	Diablo Clinical Research	Walnut Creek	California
United States	Metabolic Research Institute, Inc.	West Palm Beach	Florida

Sponsors (2)

Lead Sponsor	Collaborator
NeuroBo Pharmaceuticals Inc.	Dong-A ST Co., Ltd.

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change in Clinic Visit Pain Score at the 12 Week Visit Compared to Baseline as Assessed by the 11-point Likert Numerical Rating Scale (NRS)	Pain score was assessed by the subject using the 11-point Likert rating scale for pain (0=no pain to 10=worst possible pain) prior to conduct of any other study assessment. The change in clinic visit pain score at the 12-week visit was compared to baseline.	Baseline to 12 weeks of treatment
Secondary	Percentage Change in Clinic Visit Pain Score at the 12-week Visit Compared to Baseline as Assessed by the 11-point Likert Numerical Rating Scale (NRS)	Pain intensity was assessed by the subject before any other protocol procedures at baseline and at the 12- week visit using an 11-point Likert-type numerical rating scale for pain (0=no pain, to 10=worst possible pain) (Negative values indicate percentage reductions).	Baseline and over 12 week treatment period
Secondary	Number of Participants With at Least 30% Improvement Compared to Baseline as Assessed by the 11- Point Likert Numerical Rating Scale (NRS) at the Week 12 Clinic Visit	Pain intensity was assessed by the subject before any other protocol procedures at baseline and week 12 based on 11-point Likert-type numerical rating scale for pain (0=no pain, to 10=worst possible pain).; The number of participants who had achieved = a 30% reduction in pain from the baseline was to be compared between the treatment groups and placebo.	Baseline to 12 week treatment period
Secondary	Difference in Average Weekly Pain Score Between Dose Groups as Assessed by Daily Diary	Average 24-hour pain intensity was assessed daily based on the 11-point Likert-type numerical rating scale for pain (0=no pain, to 10=worst possible pain). Average weekly pain scores are defined as 7* [(Pain Day 1 + Pain Day 2 + …+ Pain Day n)]/n where n is the number of available diary entries for the week. The minimum pain score for a week would be 0 and the maximum would be 70.; Difference in the average weekly pain score at Week 12 is the score for each week minus the baseline .	Baseline to 12 week treatment period
Secondary	Difference in Average Weekly Most Severe Pain Score Between Dose Groups as Assessed by Daily Diary	Most severe 24-hour pain intensity was assessed daily based on the 11-point Likert-type numerical rating scale for pain (0=no pain, to 10=worst possible pain). Average weekly most severe pain scores are defined as 7* [(Pain Day 1 + Pain Day 2 + …+ Pain Day n)]/n where n is the number of available diary entries for the week. The minimum possible pain score for a week would be 0 and the maximum possible would be 70.; Difference in the average weekly pain score at Week 12 is the score at each week minus baseline .	Baseline to 12 week treatment period
Secondary	Difference in Average Weekly Overnight Pain Score Between Dose Groups as Assessed by Daily Diary	Overnight pain intensity was assessed daily based on the 11-point Likert-type numerical rating scale for pain (0=no pain, to 10=worst possible pain). Average weekly overnight pain scores are defined as 7* [(Pain Day 1 + Pain Day 2 + …+ Pain Day n)]/n where n is the number of available diary entries for the week. The minimum possible pain score for a week would be 0 and the maximum possible would be 70.; Difference in the average weekly overnight pain score at Week 12 is the score at each week minus baseline	Baseline to 12 week treatment period
Secondary	Change From Baseline Within Group- Difference in Average Weekly Pain Score Compared to Baseline as Assessed by Daily Diary	Average weekly pain intensity was assessed daily based on the 11-point Likert-type numerical rating scale for pain (0=no pain, to 10=worst possible pain). Average weekly pain scores are defined as 7* [(Pain Day 1 + Pain Day 2 + …+ Pain Day n)]/n where n is the number of available diary entries for the week. The minimum possible pain score for a week would be 0 and the maximum possible would be 70.; Difference in the average weekly pain score at Week 12 is the score at each week minus baseline.	Baseline to 12 week treatment period
Secondary	Change From Baseline Within Group-Difference in Average Weekly Overnight Pain Score Compared to Baseline as Assessed by Daily Diary	Overnight pain intensity was assessed daily based on the 11-point Likert-type numerical rating scale for pain (0=no pain, to 10=worst possible pain). Average weekly overnight pain scores are defined as 7* [(Pain Day 1 + Pain Day 2 + …+ Pain Day n)]/n where n is the number of available diary entries for the week. The minimum possible pain score for a week would be 0 and the maximum possible would be 70.; Difference in the average weekly overnight pain score at Week 12 is the score at each week minus baseline	Baseline to 12 week treatment period
Secondary	Number of Participants Considered to be Responders on Global Impression of Improvement (PGI-I) at Week 12	PGI measures the subject's overall improvement in pain. The assessment was to be completed each week during the Treatment Phase.; Global impression of improvement was assessed by the subject based on a 7 point scale (1-very much improved, 2-much improved, 3-minimally improved, 4-no change, 5-minimally worse, 6-much worse, 7-very much worse.; Responders are defined as subjects with response of "very much improved", "much improved" or "minimally improved"	Week 12
Secondary	Number of Participants Number of Participants Considered to be Responders in Clinical Global Impression (CGI) at Week 12	CGI measures global severity of illness at a given point of time and the improvement from baseline. The assessment was to be completed by the Investigator at baseline and each week during the treatment phase.; CGI responders were defined as subjects achieving a score of: (1): Very much improved or (2): Much improved or (3): Minimally improved on the clinician-rated CGI global improvement item.	Week 12
Secondary	Average Weekly Rescue Medication Use	During the Treatment Periods, subjects taking 500 mg acetaminophen or Tylenol® for severe pain recorded the frequency and dosage in the daily diary. The use of 500 mg acetaminophen or Tylenol® was recorded for Morning, Afternoon or Evening time. For each subject, the total weekly rescue medication was calculated, and it was used to assess average weekly rescue medication use.	Week 1 to Week 12